BMJ21h
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ3d
Intra-articular corticosteroids in septic arthritis: beneficial or barmy?
We read with interest the paper by Wysenbeeket al about the treatment of staphylococcal septic arthritis in rabbits by intra-articular corticosteroids in addition to antibiotics1 and would like to ...
BMJ4d
OP0040 DOSE DEPENDENT MODULATION OF PROTEOMIC SIGNATURES BY IANALUMAB IN PATIENTS WITH SJÖGREN’S DISEASE
1 Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands 2 Department of Rheumatology and Clinical Immunology, ...
BMJ4d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ4d
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...
BMJ4d
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Objectives To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue ...
BMJ4d
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
Objectives No immunomodulatory drug has been approved for primary Sjögren’s syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting ...
BMJ5d
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
BMJ5d
EULAR definition of difficult-to-treat rheumatoid arthritis
Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...
BMJ6d
Henry G Kunkel and Rheumatoid Factor
Henry Kunkel was born in Brooklyn, New York in 1916. He died in 1983 at the early age of 67. He was an outstanding clinical scholar who had a deep passion for scientific facts. Almost all his ...
BMJ6d
Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis
Department of Rheumatology, Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, University of Tel Aviv, Israel Correspondence to: Dr O Elkayam, Department of Rheumatology, Tel ...
BMJ7d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...